Ilias Kainis

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

Evdoxia Kyriazopoulou, Haralampos Milionis, Symeon Metallidis et al. · Nature Medicine · 2021 · 539 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure

Evangelos J. Giamarellos‐Bourboulis, Aline de Nooijer, Haralampos Milionis et al. · Cell Reports Medicine · 2022 · 38 citations · Full text

Veterinary Medicine, Infectious Diseases, Clinical Epidemiology +16

Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial

Karolina Akinosoglou, Antigone Kotsaki, Maria Ioanna Gounaridi et al. · EClinicalMedicine · 2022 · 23 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Interferon gamma-induced protein 10 (IP-10) for the early prognosis of the risk for severe respiratory failure and death in COVID-19 pneumonia

Charilaos Samaras, Evdoxia Kyriazopoulou, Eran Reiner et al. · Cytokine · 2022 · 17 citations · Full text

Life Sciences, Immunology, Infectious Diseases +16

Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial

Evdoxia Kyriazopoulou, Yehudit Hasin-Brumshtein, Uros Midic et al. · Critical Care · 2024 · 17 citations · Full text

Veterinary Medicine, Immunology, Pharmacotherapy +17